Combining The Web’s Most Powerful Tools To Drive Investor Interaction

Mission Social Media Relations Clients

NanoViricides Inc. (NYSE American: NNVC)

 

NanoViricides Inc. (NYSE American: NNVC) is a clinical stage global leader in the development of nanomedicine drugs against viruses. Going beyond what antibodies and immunotherapeutics do, the company's unique nanoviricide® platform technology is designed to specifically target and dismantle enveloped virus particles, offering a novel approach to treating a wide range of viral infections. NanoViricides' lead drug candidate, NV-387, is being developed for the treatment of respiratory viral infections, including RSV, COVID-19, Long COVID, and Influenza, with the company currently advancing NV-387 into Phase II human clinical trials. Another advanced candidate, NV-HHV-1, targets Shingles and represents a significant step forward in the treatment of viral diseases.

NanoViricides has also developed drug candidates specifically for COVID-19, including NV-CoV-2, which is composed of the NV-387 active pharmaceutical ingredient, and NV-CoV-2-R, which incorporates remdesivir, an FDA-approved antiviral, within its polymeric micelles. The company believes that NV-CoV-2-R has strong potential for approval, given the established safety profile of remdesivir. NanoViricides' platform technology, based on the TheraCour® nanomedicine technology licensed from TheraCour Pharma, Inc., provides broad, exclusive, and sub-licensable field licenses for various viral diseases.

Beyond its focus on respiratory infections, NanoViricides is developing treatments for a range of other viral diseases, including oral and genital herpes, viral eye diseases, H1N1 and H5N1 influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola. The company's technology platform is built on a solid foundation of licensing agreements with TheraCour Pharma, Inc., which allows NanoViricides to access and develop therapies targeting specific viruses. With its broad pipeline and innovative approach, NanoViricides aims to play a leading role in the development of next-generation antiviral therapies.

NV-387

NanoViricides is advancing its lead drug candidate, NV-387, a novel broad-spectrum antiviral designed to mimic the ubiquitous sulfated-proteoglycan (S-PG) features that over 90% of pathogenic human viruses utilize to infect human cells. NV-387 has demonstrated superior or equivalent efficacy compared to existing drugs in non-clinical animal trials against three major classes of viruses: Influenza, COVID-19, and RSV. Notably, in an RSV efficacy study, NV-387 provided complete survival and full lung protection in lethally infected mice, indicating its potential as a groundbreaking treatment where no effective options currently exist. The broad-spectrum effectiveness of NV-387 across multiple viral families suggests a highly robust antiviral agent that could potentially address the challenge of viral resistance, setting it apart from traditional medical countermeasures like vaccines, antibodies, and small molecule antivirals.

Currently, NanoViricides is completing a database audit and an external technical audit of its Phase 1a/1b human clinical trial of NV-387 in healthy subjects, with the goal of advancing to a Phase II clinical trial aimed at evaluating the drug's antiviral effectiveness in humans. The company is also exploring innovative clinical trial designs that could allow for the simultaneous evaluation of NV-387's efficacy against multiple respiratory viruses, which would be a significant advancement in clinical science. With the potential to address a market size estimated to exceed $12 billion within the next three years, NanoViricides is making substantial progress towards the commercialization and market entry of NV-387, while also seeking big pharma collaborations to expedite its programs and secure additional financing.

Market Opportunity

From an investment perspective, NanoViricides is positioned to capitalize on the growing demand for broad-spectrum antiviral therapies, particularly as the world continues to grapple with emerging and re-emerging viral threats. The company's innovative approach, using nanomaterials to directly target and dismantle viruses, offers a unique and potentially disruptive solution in a market traditionally dominated by vaccines and small molecule antivirals. With a focus on respiratory viruses, which are a significant global health concern, NanoViricides addresses critical unmet needs that could result in substantial market penetration and revenue growth, especially as governments and health organizations seek more effective countermeasures against viral pandemics.

Additionally, the versatility of NanoViricides' platform technology provides significant potential for expansion into multiple viral indications beyond its current focus areas. This adaptability not only enhances the company's ability to address a broader range of viral infections but also diversifies its revenue streams, reducing reliance on any single market. As global health challenges evolve, NanoViricides' capacity to quickly develop and scale antiviral therapies tailored to various viruses positions the company as a compelling investment opportunity with the potential for significant returns, particularly as it advances its clinical programs and moves closer to commercialization.

Leadership Team

Dr. Anil R. Diwan is the President and Chairman of NanoViricides, which he co-founded in 2005. A prolific inventor and serial entrepreneur, Dr. Diwan has over 25 years of experience in biopharmaceutical R&D and has played a pivotal role in the company's growth, including leading its 2013 uplisting to NYSE-American and spearheading various financing efforts. He is the inventor of novel polymeric micelle-based nanomedicine technologies and has founded multiple companies, including TheraCour Pharma, Inc. and AllExcel, Inc. Dr. Diwan holds a Ph.D. from Rice University and a B.Tech. from the Indian Institute of Technology, Mumbai (IIT-B), and was recognized as "Researcher of the Year" by BusinessNewHaven in 2014.

Ms. Meeta R. Vyas is the interim Chief Financial Officer of NanoViricides, bringing over 25 years of experience in finance, operations, and strategy across a diverse range of organizations, including publicly listed companies and non-revenue generating entities. She holds the distinction of being the first Indian woman to serve as CEO of a publicly listed U.S. corporation, Signature Brands, Inc., where she successfully led a turnaround strategy. Ms. Vyas has held senior leadership roles at the World-Wide Fund for Nature – India, the National Audubon Society, and General Electric (GE). She holds an MBA in Finance from Columbia University and a BS in Chemical Engineering from the Massachusetts Institute of Technology (MIT).

Investment Considerations

  • NanoViricides is pioneering a novel class of nanomedicine-based antiviral therapies, offering a unique and potentially disruptive approach to treating a broad range of viral infections.
  • The company's lead candidate, NV-387, has shown promising preclinical results against major respiratory viruses like Influenza, COVID-19, and RSV, positioning it as a strong contender in the multi-billion-dollar antiviral market.
  • NanoViricides' proprietary platform technology, based on exclusive licenses from TheraCour Pharma, provides a versatile foundation for developing treatments against numerous viral threats, enhancing the company's long-term growth potential.
  • With ongoing clinical trials and a robust pipeline targeting high-need areas such as shingles, herpes, and viral eye diseases, NanoViricides is well-positioned to capture significant market share in multiple therapeutic areas.
  • Strategic leadership under experienced executives like Dr. Anil Diwan and Ms. Meeta Vyas ensures strong governance and the ability to navigate the complexities of drug development and commercialization.

 

< Return to Clients